GLP-1 Muscle Loss: What the Trial Data Actually Shows

GLP-1 muscle loss is real, but it is widely misread. In trials, semaglutide and tirzepatide reduced both fat and lean mass, and fat fell much more. Professional-society guidance and recent reviews recommend resistance training, adequate high-quality protein and periodic monitoring to protect muscle while weight comes off. A bathroom scale cannot show which you are losing. A consistent strength log is the most practical way to track it.

Key takeaways

• In SURMOUNT-1's body-composition substudy, tirzepatide reduced fat mass by 33.9% and lean mass by 10.9% over 72 weeks (Look et al., 2025).
• A review reports that lean mass made up 20% to 50% of total weight lost across studies, and the proportion is similar for diet-based, GLP-1-based and surgical weight loss (Neeland et al., 2024).
• Guidance recommends resistance training and appropriate diet to preserve muscle, but trials built specifically for GLP-1 users are still limited and ongoing.
• A bathroom scale cannot separate muscle from fat, so your strength log is the most practical signal you have.
• Ask your clinician to track strength, body composition, food intake and side effects, starting from a baseline.

Lean mass vs muscle: what a DXA scan actually measures

A DXA scan does not count muscle directly. It estimates lean mass, which includes muscle along with water, organs and other non-fat tissue.

DXA (dual-energy X-ray absorptiometry) is a low-dose X-ray scan that sorts the body into fat, bone and lean tissue. It is the method behind most GLP-1 body-composition data. Lean mass is a broad category that includes skeletal muscle, water, organ tissue and connective tissue. One trial registry entry states that data on GLP-1 lean loss rely on a surrogate marker, fat-free mass measured by DXA (ClinicalTrials.gov NCT07154719, 2025).

Headlines about Ozempic muscle loss usually blur two different numbers:

• Lean share of weight lost: the lean portion of the total weight you lost. A narrative review found it ranged from 20% to 50% across studies, with high variability (Neeland et al., 2024).
• Percent of lean mass lost: the lean tissue lost compared with how much you started with. In SURMOUNT-1, it was 10.9% on tirzepatide (Look et al., 2025).

Neither number tells you what percentage of your muscle is gone. A headline that says "up to 40% of weight lost was lean" is describing the first number, and that lean figure still includes water and organ tissue.

How much GLP-1 muscle loss do the trials actually show?

In the main trial substudies, lean mass fell, but fat mass fell far more. In SURMOUNT-1, tirzepatide reduced fat mass by 33.9% and lean mass by 10.9%, compared with 8.2% and 2.6% on placebo (Look et al., 2025).

How to read these figures:

• STEP 1 enrolled 1,961 adults without diabetes, and mean body weight changed by -14.9% at 68 weeks with semaglutide plus lifestyle intervention (Wilding et al., 2021). The review links semaglutide to lean loss of up to 40% of weight lost, so treat any single percentage with caution (Neeland et al., 2024).
• SUSTAIN 8 shows relative lean mass rising while absolute lean mass falls, because fat dropped proportionally more.
• SURMOUNT-1 found the fat-to-lean split relatively consistent across subgroups in post hoc analyses.
• SEMALEAN measured function as well as mass. Handgrip strength improved by 4.5 kg at 12 months, and sarcopenic obesity (low muscle relative to high body fat) fell from 49% to 33% of participants. With no comparison group, it cannot show cause and effect.

These data have limits. The body-composition samples were small, and DXA measures mass, not strength. Participants were mostly women with obesity: 73% in the SURMOUNT-1 substudy and 68.9% in SEMALEAN. Separate trials also cannot settle whether tirzepatide or semaglutide costs more lean mass. For drug differences, see how semaglutide and tirzepatide differ.

Lean mass still matters: a joint advisory from four obesity and nutrition societies lists muscle and bone loss among the main challenges of GLP-1 therapy (joint Advisory, Obesity 2025). A 2026 review concludes the weight lost is largely fat, with a modest absolute lean decline and no consistent loss of strength or function, yet still recommends training, protein and monitoring, especially for higher-risk patients (European Journal of Clinical Investigation, 2026).

Strength training on semaglutide or tirzepatide: what the research supports

Guidance and reviews recommend resistance training to help preserve muscle during GLP-1 treatment. Direct evidence from GLP-1-specific trials is still limited, and some of those trials are only now underway.

The joint advisory calls for preserving muscle and bone mass through resistance training and appropriate diet (joint Advisory, 2025). The 2026 review recommends progressive resistance training, which means working against resistance and gradually increasing the challenge over time (review, 2026). One registered trial notes there is still limited prospective research on structured lifestyle programs designed to preserve muscle and bone during GLP-1 weight loss. It has no results yet (ClinicalTrials.gov NCT07554417, 2026).

Principles that fit the guidance:

• Keep training progressive. Aim to hold or slowly build working loads rather than coasting.
• Cover the major movement patterns: squat, hinge, push, pull and carry.
• Log every session, and treat holding your strength as the signal that matters.
• If you're new to lifting, get qualified coaching. If you have joint, heart or other conditions, check with a clinician first.

Side effects can get in the way. In STEP 1, 4.5% of people on semaglutide stopped treatment because of gastrointestinal events, compared with 0.8% on placebo (Wilding et al., 2021). If nausea or low appetite is draining your training, raise it with your clinician. This guide to GLP-1 side effects and when to escalate covers what's typical.

Protein on a GLP-1: how to think about your target

A 2026 review places adequate, high-quality protein alongside resistance training as a priority during GLP-1 treatment (review, 2026). Your personal target should be set with a clinician or registered dietitian, not copied from a headline.

The joint advisory focuses on adjusting to reduced food intake, preventing nutrient deficiencies and preserving muscle through diet and training, and it supports counseling with a registered dietitian (joint Advisory, 2025). This article doesn't give a grams-per-kilogram target, because the right number depends on your health, size and appetite. Individual targets matter most if you have kidney disease or another condition that changes protein needs.

Practical habits for low appetite:

• Build each meal around a protein food, and eat it first.
• If you regularly can't finish meals, tell your clinician. Persistent under-eating is worth monitoring.
• Powders can be convenient, but they don't fix low overall intake.

How to tell if you're losing muscle or fat

A bathroom scale can't tell you. Day to day, your strength log is the most useful signal. DXA is what the trials used, and home devices only estimate.

Bioimpedance devices pass a small electrical current through the body to estimate composition. Use them under the same conditions each time and ignore single readings. Also notice everyday function, such as stairs, carrying groceries or getting up off the floor, and report weakness or fatigue that seems out of proportion.

What to ask your clinician to monitor

Ask for a baseline check of strength, function and body composition, followed by periodic re-checks. The joint advisory recommends this baseline assessment (joint Advisory, 2025), and the 2026 review recommends periodic monitoring of body composition and performance (review, 2026).

Questions to bring:

• What is my baseline for body composition, strength and function, and when will we re-check?
• Is my rate of weight loss reasonable for me?
• Am I eating enough protein and total food while my appetite is low?
• Are GI side effects limiting what I eat, and should we check for nutrient deficiencies?
• Do I have higher-risk factors, such as older age or low baseline muscle, and would a registered dietitian help?

Any change to treatment is a clinical decision based on your intake and clinical review. For anything medication-related, follow your clinician's guidance and pharmacy instructions.

Who should not use GLP-1 medications

People with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN 2), or a history of pancreatitis, should not use these medications. A licensed clinician screens for this.

The FDA label for Wegovy, a brand semaglutide product, carries a boxed warning. Semaglutide caused thyroid C-cell tumors in rodents, and it is unknown whether it causes them, including MTC, in humans. The label lists a personal or family history of MTC, or MEN 2, as a contraindication. It also warns that acute pancreatitis has been observed with GLP-1 receptor agonists and that treatment should stop if pancreatitis is suspected. Acute gallbladder disease occurred in clinical trials (Wegovy prescribing information, FDA 2026). For the wider screening picture, see the GLP-1 eligibility checklist.

How access works through New Blue

New Blue offers a Semaglutide GLP-1 pathway built on clinician review, not automatic approval. New Blue is a technology and administrative services platform. Medical services are provided by independent licensed clinicians; medications are dispensed only if prescribed.

1. You complete a structured online intake about your health history, medications and goals. Adults 21+ only. Not for emergencies.
2. A licensed clinician reviews the intake asynchronously, including the MTC, MEN 2 and pancreatitis screening above. Some treatments or states may require a live visit. Consultation timing varies by clinician availability.
3. If appropriate, the clinician may prescribe. If prescribed, a licensed partner pharmacy ships the medication directly to you.

Not everyone qualifies. Eligibility depends on your intake and clinical review, and that's how it should work.

Compounded semaglutide is not FDA-approved. It has the same active ingredient as Ozempic and Wegovy, which are FDA-approved brand products, but it is not a generic of either and not equivalent to them. The trial data above come from studies of brand products. Compounded medications are prepared by state-licensed 503A compounding pharmacies or FDA-registered 503B outsourcing facilities.

Availability varies by state. The Semaglutide GLP-1 pathway ships to every state New Blue Health serves except North Dakota. The Tirzepatide GLP-1 pathway, also compounded and not FDA-approved, ships to every state New Blue Health serves except North Dakota. Check state availability. For current pricing, see the Semaglutide GLP-1 pathway page, and for the research, the semaglutide evidence summary.

Frequently Asked Questions

Does semaglutide burn muscle instead of fat?

No. In body-composition studies, semaglutide reduced fat mass more than lean mass, and the STEP 1 authors reported the same pattern (Wilding et al., 2021). Some lean mass is lost. DXA lean mass also includes water and organ tissue, so it is not a direct measure of muscle.

Is lean-mass loss worse on tirzepatide or semaglutide?

Current data cannot answer that cleanly. The main figures come from separate trials with different populations, durations and methods, so comparing them head-to-head is misleading. A review notes that the lean share of weight lost varies widely across studies (Neeland et al., 2024).

Can I keep lifting heavy on a GLP-1?

Professional-society guidance supports resistance training during GLP-1 treatment to help preserve muscle and bone (joint Advisory, 2025). How hard and how often you train depends on your experience, your health and how you're tolerating the medication. If nausea, low appetite or fatigue is cutting into training, raise it with your clinician.

Do I need a DXA scan on a GLP-1?

Not necessarily, but it's worth asking about. DXA was the body-composition method in trials such as SURMOUNT-1 (Look et al., 2025), and a joint advisory from four obesity and nutrition societies recommends a baseline assessment that includes body composition and strength (joint Advisory, 2025). Day to day, a consistent strength log is the practical proxy.

How much protein should I eat on a GLP-1?

A 2026 review recommends adequate, high-quality protein during GLP-1 treatment, but your personal target should come from a clinician or registered dietitian (review, 2026). Individual targets matter most with kidney disease or other conditions that change protein needs. When appetite is low, eat protein foods first.

Are there drugs or supplements that prevent muscle loss on GLP-1s?

The guidance and reviews cited here do not recommend any add-on drug to preserve muscle during GLP-1 treatment, and New Blue does not offer one for this purpose. They focus on resistance training, diet and monitoring. Be cautious of any pitch that promises to protect your muscle with a powder or an injection.

Sources

1. Once-Weekly Semaglutide in Adults with Overweight or Obesity. The New England Journal of Medicine, 2021. https://pubmed.ncbi.nlm.nih.gov/33567185/
2. Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies. Diabetes, Obesity and Metabolism, 2024. https://doi.org/10.1111/dom.15728
3. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes, Obesity and Metabolism, 2025. https://pubmed.ncbi.nlm.nih.gov/39996356/
4. Nutritional priorities to support GLP-1 therapy for obesity: A joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Obesity, 2025. https://doi.org/10.1002/oby.24336
5. Muscle health in the modern era of incretin-based therapies. European Journal of Clinical Investigation, 2026. https://pmc.ncbi.nlm.nih.gov/articles/PMC12825403/
6. Impact of Semaglutide on fat mass, lean mass and muscle function in patients with obesity: The SEMALEAN study. Diabetes, Obesity and Metabolism, 2026. https://pmc.ncbi.nlm.nih.gov/articles/PMC12673431/
7. WEGOVY (semaglutide) prescribing information. U.S. Food and Drug Administration, 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s033lbl.pdf
8. Combatting Muscle Loss in Obese Adult Patients on GLP-1 Medications Through Dietary Counseling and Exercise During Treatment. ClinicalTrials.gov, 2026. https://clinicaltrials.gov/study/NCT07554417
9. GLP-1R Actions on Muscle and the Skeleton. ClinicalTrials.gov, 2025. https://clinicaltrials.gov/study/NCT07154719

Medical disclaimer: This article is educational and is not medical advice. Treatment decisions are made by a licensed clinician based on your intake and clinical review. New Blue Health is a technology and administrative services platform, not a medical provider.